Using host receptor as a decoy to treat COVID-19: a solution for immune escape?Article Published on 2022-11-082022-11-16 Journal: EMBO Molecular Medicine [Category] COVID19(2023년), SARS, 변종, [키워드] ACE2 antibodies COVID-19 pandemic Critical dose driven by Efficacy evade host receptor immune Immunity IMPROVE inoculated K18-hACE2 transgenic mice Lung injury Medicine neutralizing antibody omicron pandemic reduce survival target the SARS-CoV-2 the vaccine therapeutic Therapies treat variant variants [DOI] 10.15252/emmm.202216818 PMC 바로가기
Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare DiseasesArticle Published on 2022-11-012022-11-16 Journal: Therapeutic innovation & regulatory science [Category] 신약개발, [키워드] advance affected approach children clinical trials COVID-19 COVID-19 pandemic development disease drug ecosystem Efficacy effort engage equity facilitate Follow-up include initiative key factor lack outcome measure Patient pediatric pediatric drug development promote Public public health rare disease rare diseases Regulatory Regulatory policy. Study design Therapies Trial trials [DOI] 10.1007/s43441-022-00409-w PMC 바로가기
IgA nephropathy with glomerular capillary IgA deposition following SARS-CoV-2 mRNA vaccination: a report of three casesArticle Published on 2022-11-012022-11-15 Journal: CEN case reports [Category] COVID19(2023년), SARS, 진단, [키워드] acute deterioration acute exacerbation acute respiratory syndrome addition coronavirus COVID-19 de novo diagnosed glomerular Hematuria histological IgA IgA nephropathy kidney lesions mRNA mRNA vaccine mRNA vaccine. nephropathy Patient proliferation relapsing SARS-CoV-2 SARS-CoV-2 vaccination Therapies Urinalysis Vaccinations [DOI] 10.1007/s13730-022-00707-0 PMC 바로가기
An overview of pivotal trials and real-world evidence for CD20-depleting therapy in multiple sclerosis : Immunotherapy with rituximab, ocrelizumab, and ofatumumabArticle Published on 2022-11-012022-11-15 Journal: Wiener medizinische Wochenschrift (1946) [Category] 바이오마커, 진단, [키워드] addition Autoimmunitiy brain tissue Central nervous system chronic inflammatory disease COVID-19 pandemic Demyelination disadvantage disease effective Evidence MRI Multiple multiple sclerosis neurodegeneration Neuroimmunology Patient primary mechanism Primary progressive multiple sclerosis provide Relapsing-remitting multiple sclerosis. Research T cell therapeutic Therapeutic approach Therapies therapy Treatment Trial [DOI] 10.1007/s10354-022-00939-w PMC 바로가기
Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sourcesArticle Published on 2022-10-292022-11-15 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] anti-SARS-CoV-2 Antibody titer CCP collected convalescent plasma COVID-19 Donor dose effective geometric geometric mean titer Immune escape Immunocompromised implication Infection lesson monoclonal antibodies monoclonal antibody mRNA vaccine neutralization neutralize Neutralizing Neutralizing antibody titer omicron Outpatient pandemic plasma plasma activity provide recipients reduction representing SARS-CoV-2 variant sera subject therapeutic Therapies uninfected vaccinee variant variants of concern [DOI] 10.1038/s41467-022-33864-y PMC 바로가기
Type D lymphomatoid papulosis with pityriasis lichenoides et varioliformis acuta-like features in a child with parvovirus infection: a controversial diagnosis in the spectrum of lymphoid proliferations: case report and literature reviewArticle Published on 2022-10-282022-11-16 Journal: Italian Journal of Pediatrics [Category] COVID19(2023년), SARS, 치료기술, [키워드] Administered Alanine antigenic Aspartate aminotransferase Bilirubin C-reactive protein Case report CD8+/CD30+ cells children clinical response clinical suspicion Critical cytokine profile Cytokines Department Diagnosis differential diagnosis discharged disease disorder Emergency erythematous feature Fever histological history Hospitalized IFN-γ IL-10 IL-6 immunoglobulin M infectious agent infiltration introduced Laboratory test lesion lesions limits literature review lymphoid lymphomatoid Lymphomatoid papulosis lymphoproliferative Lymphoproliferative cutaneous disorders marker mechanism monoclonal morphologically necrotic Parvovirus parvovirus B19 pathogenic Perspective phenotype pityriasis lichenoides et varioliformis acuta. polymerase chain reaction positive response proliferation Rash recorded regions reported representing returned SARS-CoV-2 antigen separated skin lesions steroid Support Symptom systemic corticosteroid T-cell receptor Therapies Treatment Type Type D [DOI] 10.1186/s13052-022-01371-x PMC 바로가기
Recombinant Protein Micelles to Block Transduction by SARS-CoV-2 PseudovirusArticle Published on 2022-10-252022-11-16 Journal: ACS Nano [Category] COVID19(2023년), SARS, 변종, [키워드] antibody Baker block Cell cloned Combination Concentration DAVID Delta delta variant E. coli expressing functional protein Genetic human cells Infection Laboratory micelle Mini-Proteins molecular multifunctional multivalent Multivalent Micelles N-terminus non-toxic Oleosin peptides performed Precision Protein Proteins receptor recombinant Recombinant protein reduced reducing S1 protein SARS-CoV-2 SARS-CoV-2 pseudovirus scattering Seattle Self-Assembly. the SARS-CoV-2 virus the Spike Therapies transduction variant wild-type [DOI] 10.1021/acsnano.2c09015 PMC 바로가기
Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective studyArticle Published on 2022-10-202022-11-15 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] adverse events Algorithm antibody Antiviral antiviral drug antivirals approved benefit Calabria case sery clinical clinical evolution Combination combination therapy combined use coronavirus disease COVID-19 COVID-19 progression drug Early therapies early treatment effective Effectiveness Efficacy escape mutant group Health services hospital Hospital admission hospitalisation Hospitalized hypothesised Immunocompromised immunocompromised individuals implication increase in lesson mAb mAbs malignancy monoclonal antibodies monoclonal antibody monotherapy Patient patients patients treated progression provided receive reduce reported Retrospective study SARS-CoV-2 SARS-CoV-2 genome Support symptom onset Territorial health services. Therapies therapy treated treated patient Treatment [DOI] 10.1186/s12879-022-07774-9 PMC 바로가기
Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor InteractionArticle Published on 2022-10-192022-11-15 Journal: International Journal of Molecular Sciences [Category] COVID19(2023년), SARS, 신약개발, 치료제, [키워드] ACE2 ACE2 receptor acute respiratory syndrome addition anticipated antiviral efficacy blocker blocking cell entry Clinical use Combination component coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 demonstrated develop disrupting docking drugs effective Effectiveness Efficacy effort ELISA ENhance Future HEK293T cells in silico Infection inhibit inhibitor inhibitors Interaction isolate kuwanon C lack mechanism of action Morus Alba Morus alba L. potent Prevent Pseudotyped virus receptor Replication RNA SARS-CoV-2 SARS-CoV-2 spike several limitation severe acute respiratory syndrome coronavirus 2 significantly spike Spike protein spike protein. spike S1 RBD supported target tested the SARS-CoV-2 Therapies Vero cells [DOI] 10.3390/ijms232012516 PMC 바로가기
A machine learning approach utilizing DNA methylation as an accurate classifier of COVID-19 disease severityArticle Published on 2022-10-192022-11-16 Journal: Scientific Reports [Category] 변종, [키워드] applied approach average benefit Classifier Cohort COVID-19 COVID-19 disease COVID-19 disease severity COVID-19 pandemic dataset DNA methylation Epigenetic external validation Gene Expression Omnibus identify increased risk individual logit Methylation methylation site NCBI non-infected outcome pathology platform Pneumonia processed produced provide random forest classification Receiver operator characteristic severe COVID-19 disease Therapies unique utility Vaccine variant [DOI] 10.1038/s41598-022-22201-4 PMC 바로가기